| Market Capitalization (Millions $) |
787 |
| Shares
Outstanding (Millions) |
112 |
| Employees |
40 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-50 |
| Cash Flow (TTM) (Millions $) |
30 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Shattuck Labs Inc is a biotechnology company that is focused on developing next-generation therapies for cancer treatment. The company was founded in 2016 and is headquartered in Austin, Texas. Shattuck Labs has a broad range of expertise in cancer biology, immunotherapy and drug development.
The company's lead product candidate is called SL-172154, which is an immunotherapy that targets the CD47 trimerization domain. This drug facilitates the phagocytosis of cancer cells by immune cells, which helps to promote an anti-tumor immune response. SL-172154 is currently in Phase 1 clinical trials for patients with solid tumors.
Shattuck Labs has also developed a proprietary platform called Agonist Redirected Checkpoint (ARC) that allows for the generation of novel immunotherapies. The ARC platform combines an agonist ligand that activates immune cells with a checkpoint inhibitor that helps to prevent immunosuppression. This technology can also enable targeted drug delivery to cancer cells, reducing the potential for off-target effects.
In addition to their pipeline of drug candidates, Shattuck Labs has established strategic partnerships with companies such as Takeda Pharmaceuticals and Astellas Pharma. Through these partnerships, the company is able to access additional resources and expertise to further develop their immuno-oncology therapies.
Overall, Shattuck Labs Inc is a dynamic company that is positioned for success in the emerging field of cancer immunotherapy. Their innovative platform technology and promising lead product candidate make them a company to watch in the biotech industry.
Company Address: 500 W. 5th Street Austin 78701 TX
Company Phone Number: 900-4690 Stock Exchange / Ticker: NASDAQ STTK
|
1.98% 